• LAST PRICE
    3.9000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.6600/ 1
  • Ask / Lots
    4.1700/ 1
  • Open / Previous Close
    3.9200 / 3.9000
  • Day Range
    Low 3.7600
    High 4.0100
  • 52 Week Range
    Low 1.5600
    High 4.3800
  • Volume
    57,605
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.9
TimeVolumeALIM
10:06 ET1003.92
10:28 ET1003.92
10:39 ET11003.87
10:46 ET15003.865
11:08 ET2003.77
11:09 ET145003.78
11:11 ET33003.81
11:13 ET2003.83
11:15 ET1003.86
11:18 ET1003.89
11:20 ET164233.85
11:31 ET2003.88
11:36 ET1003.89
11:42 ET9123.89
11:58 ET1003.89
12:09 ET2003.89
12:20 ET2003.9
12:41 ET2003.94
12:43 ET4003.94
12:45 ET1004.005
12:50 ET19003.925
01:12 ET2003.915
01:37 ET1003.955
01:39 ET5003.8613
01:48 ET24543.9512
01:57 ET1003.96
02:27 ET2003.97
02:29 ET3214.01
02:49 ET1004.01
03:09 ET1004.01
03:23 ET1003.96
03:27 ET25773.95
03:39 ET1003.9
03:41 ET2003.945
03:52 ET1003.88
03:54 ET4003.91
03:57 ET1003.95
03:59 ET2073.9
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALIM
Alimera Sciences Inc
204.2M
-1.8x
---
United StatesGTHX
G1 Therapeutics Inc
225.5M
-4.5x
---
United StatesCDXC
Chromadex Corp
262.1M
-52.8x
---
United StatesCDXS
Codexis Inc
245.4M
-3.1x
---
United StatesIPHA
Innate Pharma SA
191.3M
-31.7x
---
United StatesPSNL
Personalis Inc
75.3M
-0.7x
---
As of 2024-03-29

Company Information

Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.

Contact Information

Headquarters
STE 290, 6120 WINDWARD PARKWAYALPHARETTA, GA, United States 30005
Phone
678-990-5740
Fax
678-990-5744

Executives

Non-Executive Chairman of the Board
C. Daniel Myers
President, Chief Executive Officer, Director
Richard Eiswirth
Chief Financial Officer
Elliot Maltz
President - International Operations
Philip Ashman
Chief Operating Officer, Director
Jason Werner

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$204.2M
Revenue (TTM)
$80.8M
Shares Outstanding
52.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.18
EPS
$-2.16
Book Value
$0.88
P/E Ratio
-1.8x
Price/Sales (TTM)
2.5
Price/Cash Flow (TTM)
---
Operating Margin
-3.73%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.